Table 7Summary of Baseline Characteristics in the Griphon Study

CharacteristicSelexipag
N = 574
Placebo
N = 582
Female, n (%)457 (80)466 (80)
Mean age (SD), years48 (15)48 (16)
Ethnicity
  Caucasian or Hispanic427 (74)438 (75)
  Asian125 (22)120 (21)
Mean time since PAH diagnosis (SD), years2.3 (3.5)2.5 (3.8)
PAH Classification, n (%)
  Idiopathic312 (54)337 (58)
  Heritable13 (2)13 (2)
  Drug or toxin-induced17 (3)10 (2)
  Connective tissue disease167 (29)167 (29)
  Congenital heart disease60 (10)50 (9)
  HIV5 (1)5 (1)
WHO Functional Class
  I4 (1)5 (1)
  II274 (48)255 (44)
  III293 (51)314 (54)
  IV3 (< 1)8 (1)
Mean 6MWD (SD), m358 (76)348 (83)
Mean Borg Dyspnea Index (SD)
PAH medications concomitant at baseline, n (%)
  None112 (20)124 (21)
  ERA monotherapy94 (16)76 (13)
  PDE5 inhibitor monotherapy189 (33)185 (32)
  ERA and PDE5 inhibitor179 (31)197 (34)

6MWD = six-minute walk distance; ERA = endothelin receptor antagonists; PAH = pulmonary arterial hypertension; PDE5 = phosphodiesterase 5; SD = standard deviation; WHO = World Health Organization.

Source: Sitbon 2015,9 Clinical Study Report.8

From: 3, Results

Cover of Clinical Review Report: Slexipag (Uptravi)
Clinical Review Report: Slexipag (Uptravi) [Internet].
Copyright © 2017 Canadian Agency for Drugs and Technologies in Health.

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian Copyright Act and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.